Skip to main content
Erschienen in: Die Radiologie 5/2020

30.03.2020 | Computertomografie | Leitthema

Hybridbildgebung bei abdominellen Erkrankungen

verfasst von: Krista Elise Suarez-Weiss, Alexander Herold, Debra Gervais, Edwin Palmer, Bárbara Amorim, Joseph D. King, Li Weier, Tajmir Shahein, Hanna Bernstine, Liran Domachevsk, Lina Garcia Cañamaque, Lale Umutlu, Ken Herrmann, David Groshar, Onofrio A Catalano, MD, PhD

Erschienen in: Die Radiologie | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine adäquate Bildgebung ist für die Detektion mitunter kleinster Läsionen, die non-invasive Charakterisierung von fokalen und diffusen Veränderungen, sowie die Planung chirurgischer Eingriffe von entscheidender Bedeutung. Zur Bewältigung dieser Aufgaben werden verschiedene bildgebende Verfahren wie die Multidetektor-Computertomographie (MDCT), Magnetresonanztomographie (MRT) und Positronen-Emissions-Tomographie/Computertomographie (PET/CT) eingesetzt, die wichtige morphologische, funktionelle oder metabolische Informationen liefern. In letzter Zeit gewinnt die PET/MRT aufgrund der Möglichkeit von Kombination hochauflösender Bildgebung und metabolischer Bildgebung zunehmend an Aufmerksamkeit. Die PET/MRT ist eine neuartige Hybridbildgebungstechnologie, die in naher Zukunft eine zentrale Rolle bei der klinischen Behandlung von onkologischen und entzündlichen Abdomen-Becken-Erkrankungen spielen könnte. Trotz der noch begrenzten Anzahl publizierter klinischer Studien hat sich die PET/MRT bei einer Vielzahl von onkologischen Erkrankungen als zumindest gleichwertig wie PET/CT und MRT als Einzeluntersuchung erwiesen. In ausgewählten und fokussierten klinischen Studien wurde zudem nachgewiesen, dass es die derzeitige Standardbildgebung beispielsweise in der Beurteilung von Cholangiokarzinomen, Lebermetastasen sowie unbehandelten und behandelten Rektumkarzinomen übertrifft. Dies hat sich in einigen Studien auch auf das therapeutische Management ausgewirkt. Daher ist die PET/MRT in einigen Institutionen zur neue Standardbildgebungsmethode, z. B. bei unbehandelten intrahepatischen Cholangiokarzinomen sowie vor komplizierten Leberoperationen geworden.
Literatur
1.
Zurück zum Zitat Aklilu M, Eng C (2011) The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8(11):649–659PubMedCrossRef Aklilu M, Eng C (2011) The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8(11):649–659PubMedCrossRef
2.
Zurück zum Zitat Amorim BJ, Theodore SH, Blaszkowsky LS, Ferrone CR, Berger DL, Bordeianou LG, Ricciardi R et al (2019) Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging 46(11):2260–2269PubMedCrossRef Amorim BJ, Theodore SH, Blaszkowsky LS, Ferrone CR, Berger DL, Bordeianou LG, Ricciardi R et al (2019) Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging 46(11):2260–2269PubMedCrossRef
3.
Zurück zum Zitat Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS (2003) Non–small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533PubMedCrossRef Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS (2003) Non–small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533PubMedCrossRef
4.
Zurück zum Zitat Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, Muse V et al (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol 41(7):1338–1348CrossRef Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, Muse V et al (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol 41(7):1338–1348CrossRef
6.
Zurück zum Zitat Brendle C, Schwenzer NF, Rempp H, Schmidt H, Pfannenberg C, la Fougère C, Nikolaou K, Schraml C (2016) Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-015-3137-z CrossRefPubMed Brendle C, Schwenzer NF, Rempp H, Schmidt H, Pfannenberg C, la Fougère C, Nikolaou K, Schraml C (2016) Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-015-3137-z CrossRefPubMed
7.
Zurück zum Zitat Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, Geraint TW (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227(2):371–377PubMedCrossRef Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, Geraint TW (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227(2):371–377PubMedCrossRef
8.
Zurück zum Zitat Catalano OA, Coutinho AM, Sahani DV, Vangel MG, Gee MS, Hahn PF, Witzel T et al (2017) Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol 42(4):1141–1151CrossRef Catalano OA, Coutinho AM, Sahani DV, Vangel MG, Gee MS, Hahn PF, Witzel T et al (2017) Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol 42(4):1141–1151CrossRef
9.
Zurück zum Zitat Catalano OA, Gee MS, Emanuele N, Selvaggi F, Pellino G, Cuocolo A, Luongo A et al (2016) Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease. Radiology 278(3):792–800PubMedCrossRef Catalano OA, Gee MS, Emanuele N, Selvaggi F, Pellino G, Cuocolo A, Luongo A et al (2016) Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease. Radiology 278(3):792–800PubMedCrossRef
10.
Zurück zum Zitat Catalano OA, Wu V, Mahmood U, Signore A, Vangel M, Soricelli A, Salvatore M, Gervais D, Rosen BR (2018) Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nuclear Med Mol Imaging 8(1):62–69 Catalano OA, Wu V, Mahmood U, Signore A, Vangel M, Soricelli A, Salvatore M, Gervais D, Rosen BR (2018) Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nuclear Med Mol Imaging 8(1):62–69
11.
Zurück zum Zitat Catalano OA, Rosen BR, Sahani DV, Hahn PF, Guimaraes AR, Vangel MG, Nicolai E, Soricelli A, Salvatore M (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology. https://doi.org/10.1148/radiology.13131306 CrossRefPubMed Catalano OA, Rosen BR, Sahani DV, Hahn PF, Guimaraes AR, Vangel MG, Nicolai E, Soricelli A, Salvatore M (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology. https://​doi.​org/​10.​1148/​radiology.​13131306 CrossRefPubMed
12.
Zurück zum Zitat Catalano O, Kilcoyne A, Signore A, Mahmood U, Rosen B (2018) Lower gastrointestinal tract applications of PET/computed tomography and PET/MR imaging. Radiol Clin North Am 56(5):821–834PubMedCrossRef Catalano O, Kilcoyne A, Signore A, Mahmood U, Rosen B (2018) Lower gastrointestinal tract applications of PET/computed tomography and PET/MR imaging. Radiol Clin North Am 56(5):821–834PubMedCrossRef
13.
Zurück zum Zitat Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1261–1268PubMedCrossRef Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1261–1268PubMedCrossRef
15.
Zurück zum Zitat Choi M, Kollepara SLS, Heilbrun LK, Smith D, Shields AF, Philip PA (2015) PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 14(1):35–40PubMedCrossRef Choi M, Kollepara SLS, Heilbrun LK, Smith D, Shields AF, Philip PA (2015) PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 14(1):35–40PubMedCrossRef
16.
Zurück zum Zitat Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52(12):1914–1922PubMedCrossRef Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52(12):1914–1922PubMedCrossRef
19.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef
20.
Zurück zum Zitat Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953PubMedCrossRef Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953PubMedCrossRef
24.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R et al (2004) Cytoreductive surgery combined with perioperative Intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. https://doi.org/10.1200/jco.2004.10.012 CrossRefPubMed Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R et al (2004) Cytoreductive surgery combined with perioperative Intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. https://​doi.​org/​10.​1200/​jco.​2004.​10.​012 CrossRefPubMed
25.
Zurück zum Zitat Heacock L, Weissbrot J, Raad R, Campbell N, Friedman KP, Ponzo F, Chandarana H (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 204(4):842–848PubMedPubMedCentralCrossRef Heacock L, Weissbrot J, Raad R, Campbell N, Friedman KP, Ponzo F, Chandarana H (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 204(4):842–848PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Horvat N, Petkovska I, Gollub MJ (2018) MR imaging of rectal cancer. Radiol Clin North Am 56(5):751–774PubMedCrossRef Horvat N, Petkovska I, Gollub MJ (2018) MR imaging of rectal cancer. Radiol Clin North Am 56(5):751–774PubMedCrossRef
28.
Zurück zum Zitat Hu J, Chen F‑Y, Zhou K‑Q, Zhou C, Cao Ya, Hui-Chuan S, Fan J, Zhou J, Wang Z (2017) Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. Oncotarget 8(69):113817–113827PubMedPubMedCentral Hu J, Chen F‑Y, Zhou K‑Q, Zhou C, Cao Ya, Hui-Chuan S, Fan J, Zhou J, Wang Z (2017) Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. Oncotarget 8(69):113817–113827PubMedPubMedCentral
29.
Zurück zum Zitat Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade Non-Hodgkin’s Lymphoma (NHL). Ann Oncol 12(6):825–830PubMedCrossRef Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade Non-Hodgkin’s Lymphoma (NHL). Ann Oncol 12(6):825–830PubMedCrossRef
30.
Zurück zum Zitat Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee JC, Jang J‑Y, Kim S‑W, Ryu JK, Lee K‑B (2017) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology. https://doi.org/10.1148/radiol.2016152798 CrossRefPubMed Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee JC, Jang J‑Y, Kim S‑W, Ryu JK, Lee K‑B (2017) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology. https://​doi.​org/​10.​1148/​radiol.​2016152798 CrossRefPubMed
31.
Zurück zum Zitat Kang B, Jeong ML, Sub YS, Woo S, Hur BY, Jeon JH, Paeng JC (2016) Added value of integrated whole-body PET/MRI for evaluation of colorectal cancer: comparison with contrast-enhanced MDCT. Am J Roentgenol 206(1):W10–W20CrossRef Kang B, Jeong ML, Sub YS, Woo S, Hur BY, Jeon JH, Paeng JC (2016) Added value of integrated whole-body PET/MRI for evaluation of colorectal cancer: comparison with contrast-enhanced MDCT. Am J Roentgenol 206(1):W10–W20CrossRef
32.
Zurück zum Zitat Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC et al (2009) FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 39(2):134–142PubMedCrossRef Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC et al (2009) FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 39(2):134–142PubMedCrossRef
33.
Zurück zum Zitat Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68ga-DOTATATE (DOTA-DPhe1, Tyr3-Octreotate) and 18F-FDG. Cancer 112(11):2447–2455PubMedCrossRef Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68ga-DOTATATE (DOTA-DPhe1, Tyr3-Octreotate) and 18F-FDG. Cancer 112(11):2447–2455PubMedCrossRef
34.
Zurück zum Zitat Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23(20):4553–4560PubMedCrossRef Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23(20):4553–4560PubMedCrossRef
35.
Zurück zum Zitat van Kessel CS, Buckens CFM, van den Bosch MAAJ, van Leeuwen MS, van Hillegersberg R, Verkooijen HMV (2012) Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19(9):2805–2813PubMedPubMedCentralCrossRef van Kessel CS, Buckens CFM, van den Bosch MAAJ, van Leeuwen MS, van Hillegersberg R, Verkooijen HMV (2012) Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19(9):2805–2813PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Kim JY, Myung-Hwan K, Tae YL, Hwang CY, Kim JS, Yun S‑C, Lee SS, Seo DW, Lee SK (2008) Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterology 103(5):1145–1151CrossRef Kim JY, Myung-Hwan K, Tae YL, Hwang CY, Kim JS, Yun S‑C, Lee SS, Seo DW, Lee SK (2008) Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterology 103(5):1145–1151CrossRef
37.
Zurück zum Zitat Kirchner J, Kirchner EM, Goltz JP, Lorenz V‑W, Kickuth R (2011) Prevalence of enlarged mediastinal lymph nodes in heavy smokers—a comparative study. Eur Radiol 21(8):1594–1599PubMedCrossRef Kirchner J, Kirchner EM, Goltz JP, Lorenz V‑W, Kickuth R (2011) Prevalence of enlarged mediastinal lymph nodes in heavy smokers—a comparative study. Eur Radiol 21(8):1594–1599PubMedCrossRef
38.
Zurück zum Zitat Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507PubMedCrossRef Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507PubMedCrossRef
39.
Zurück zum Zitat Lee DH, Lee JM, Hur BY, Joo I, Yi N‑J, Suh K‑S, Kang KW, Han JK (2016) Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging. Radiology 280(3):782–792PubMedCrossRef Lee DH, Lee JM, Hur BY, Joo I, Yi N‑J, Suh K‑S, Kang KW, Han JK (2016) Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging. Radiology 280(3):782–792PubMedCrossRef
40.
Zurück zum Zitat Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23(9):2038–2048PubMedCrossRef Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23(9):2038–2048PubMedCrossRef
41.
Zurück zum Zitat Li Y, Langhorst J, Koch AK, Demircioglu A, Nensa F, Kirchner J, Beiderwellen K et al (2019) Assessment of Ileocolonic inflammation in Crohn’s disease: which surrogate marker is better-maRIA, Clermont, or PET/MR index? Initial results of a feasibility trial. J Nucl Med 60(6):851–857PubMedPubMedCentralCrossRef Li Y, Langhorst J, Koch AK, Demircioglu A, Nensa F, Kirchner J, Beiderwellen K et al (2019) Assessment of Ileocolonic inflammation in Crohn’s disease: which surrogate marker is better-maRIA, Clermont, or PET/MR index? Initial results of a feasibility trial. J Nucl Med 60(6):851–857PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A‑M (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259PubMedPubMedCentralCrossRef Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A‑M (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68PubMedCrossRef Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68PubMedCrossRef
47.
Zurück zum Zitat Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, Scherr M, Reiser MF (2007) Staging of renal cell carcinoma. Eur Radiol 17(9):2268–2277PubMedCrossRef Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, Scherr M, Reiser MF (2007) Staging of renal cell carcinoma. Eur Radiol 17(9):2268–2277PubMedCrossRef
48.
Zurück zum Zitat Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Motoori K, Ueda T (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239(1):122–130PubMedCrossRef Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Motoori K, Ueda T (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239(1):122–130PubMedCrossRef
49.
Zurück zum Zitat Ozawa Y, Hara M, Sakurai K, Nakagawa M, Tamaki T, Nishio M, Shibamoto Y (2010) Diagnostic accuracy of 18F-2-Deoxy-Fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 51(2):150–155PubMedCrossRef Ozawa Y, Hara M, Sakurai K, Nakagawa M, Tamaki T, Nishio M, Shibamoto Y (2010) Diagnostic accuracy of 18F-2-Deoxy-Fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 51(2):150–155PubMedCrossRef
51.
Zurück zum Zitat Padhani AR, Koh D‑M, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research direction. Radiology 261(3):700–718PubMedCrossRef Padhani AR, Koh D‑M, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research direction. Radiology 261(3):700–718PubMedCrossRef
52.
Zurück zum Zitat Park J‑W, Kim JH, Kim SK, Kang KW, Park KW, Choi J‑I, Lee WJ, Kim C‑M, Nam BH (2008) A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma. J Nucl Med 49(12):1912–1921PubMedCrossRef Park J‑W, Kim JH, Kim SK, Kang KW, Park KW, Choi J‑I, Lee WJ, Kim C‑M, Nam BH (2008) A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma. J Nucl Med 49(12):1912–1921PubMedCrossRef
53.
Zurück zum Zitat Pellino G, Nicolai E, Catalano OA, Campione S, D’Armiento FP, Salvatore M, Cuocolo A, Selvaggi F (2016) PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis 10(3):277–285PubMedCrossRef Pellino G, Nicolai E, Catalano OA, Campione S, D’Armiento FP, Salvatore M, Cuocolo A, Selvaggi F (2016) PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis 10(3):277–285PubMedCrossRef
54.
Zurück zum Zitat Plodeck V, Rahbari NN, Weitz J, Radosa CG, Laniado M, Hoffmann R‑T, Zöphel K et al (2019) FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences. Eur Radiol 29(1):422–428PubMedCrossRef Plodeck V, Rahbari NN, Weitz J, Radosa CG, Laniado M, Hoffmann R‑T, Zöphel K et al (2019) FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences. Eur Radiol 29(1):422–428PubMedCrossRef
55.
Zurück zum Zitat Ponisio MR, McConathy J, Laforest R, Khanna G (2016) Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol 46(9):1258–1268PubMedPubMedCentralCrossRef Ponisio MR, McConathy J, Laforest R, Khanna G (2016) Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol 46(9):1258–1268PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111PubMedCrossRef Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111PubMedCrossRef
57.
Zurück zum Zitat Ruhlmann V, Poeppel TD, Brandt AS, Grueneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-016-3376-7 CrossRefPubMed Ruhlmann V, Poeppel TD, Brandt AS, Grueneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L (2016) Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-016-3376-7 CrossRefPubMed
60.
Zurück zum Zitat von Schulthess GK, Schlemmer H‑PW (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(1):3–9CrossRef von Schulthess GK, Schlemmer H‑PW (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(1):3–9CrossRef
61.
Zurück zum Zitat Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, Malhotra A (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37(7):649–655PubMedCrossRef Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, Malhotra A (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37(7):649–655PubMedCrossRef
62.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30PubMedCrossRef Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30PubMedCrossRef
63.
Zurück zum Zitat Slart RHJA1, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees et al (2018) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET interest group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-3973-8 CrossRef Slart RHJA1, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees et al (2018) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET interest group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-018-3973-8 CrossRef
64.
Zurück zum Zitat Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L (2011) Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 31(2):569–583PubMedCrossRef Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L (2011) Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 31(2):569–583PubMedCrossRef
65.
Zurück zum Zitat Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease Activity and Vascular Involvement in Retroperitoneal Fibrosis: First Experience with Fully Integrated 18F-Fluorodeoxyglucose Positron Emission Tomography/magnetic Resonance Imaging Compared to Clinical and Laboratory Parameters. Clin Exp Rheumatol 35(Suppl 103 (1)):146–154PubMed Thuermel K, Einspieler I, Wolfram S, Moog P, Meier R, Schwaiger M, Heemann U (2017) Disease Activity and Vascular Involvement in Retroperitoneal Fibrosis: First Experience with Fully Integrated 18F-Fluorodeoxyglucose Positron Emission Tomography/magnetic Resonance Imaging Compared to Clinical and Laboratory Parameters. Clin Exp Rheumatol 35(Suppl 103 (1)):146–154PubMed
66.
Zurück zum Zitat Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho Z‑H, Alavi A (2013) PET/MR imaging: technical aspects and potential clinical applications. Radiology 267(1):26–44PubMedCrossRef Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho Z‑H, Alavi A (2013) PET/MR imaging: technical aspects and potential clinical applications. Radiology 267(1):26–44PubMedCrossRef
67.
Zurück zum Zitat Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811–1817PubMed Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811–1817PubMed
68.
Zurück zum Zitat Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336PubMedPubMedCentralCrossRef Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncol 15(Suppl 4):5–13CrossRef Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncol 15(Suppl 4):5–13CrossRef
71.
Zurück zum Zitat Wenter V, Sommer NN, Kooijman H, Maurus S, Treitl M, Czihal M, Dechant C, Unterrainer M, Albert NL, Treitl KM (2018) Clinical value of [18F] FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. Q J Nucl Med Mol Imaging. https://doi.org/10.23736/S1824-4785.18.03036-4 Wenter V, Sommer NN, Kooijman H, Maurus S, Treitl M, Czihal M, Dechant C, Unterrainer M, Albert NL, Treitl KM (2018) Clinical value of [18F] FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. Q J Nucl Med Mol Imaging. https://​doi.​org/​10.​23736/​S1824-4785.​18.​03036-4
72.
Zurück zum Zitat Wilhelmsen M, Kring T, Jorgensen LN, Rørbæk Madsen M, Jess P, Bulut O, Nielsen KT, Lindbjerg Andersen C, Nielsen HJ (2014) Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol 49(12):1399–1408PubMedCrossRef Wilhelmsen M, Kring T, Jorgensen LN, Rørbæk Madsen M, Jess P, Bulut O, Nielsen KT, Lindbjerg Andersen C, Nielsen HJ (2014) Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol 49(12):1399–1408PubMedCrossRef
73.
Zurück zum Zitat Wudel LJ Jr, Delbeke D, Morris D, Rice M et al (2003) The role of [\^ sup 18\^ F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma/discussion. Am Surg 69(2):117PubMed Wudel LJ Jr, Delbeke D, Morris D, Rice M et al (2003) The role of [\^ sup 18\^ F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma/discussion. Am Surg 69(2):117PubMed
Metadaten
Titel
Hybridbildgebung bei abdominellen Erkrankungen
verfasst von
Krista Elise Suarez-Weiss
Alexander Herold
Debra Gervais
Edwin Palmer
Bárbara Amorim
Joseph D. King
Li Weier
Tajmir Shahein
Hanna Bernstine
Liran Domachevsk
Lina Garcia Cañamaque
Lale Umutlu
Ken Herrmann
David Groshar
Onofrio A Catalano, MD, PhD
Publikationsdatum
30.03.2020
Verlag
Springer Medizin
Erschienen in
Die Radiologie / Ausgabe 5/2020
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-020-00660-y

Weitere Artikel der Ausgabe 5/2020

Die Radiologie 5/2020 Zur Ausgabe

Einführung zum Thema

Hybridbildgebung

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Mitteilungen des Berufsverbandes der Deutschen Radiologen

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009